Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rallybio
Biotech
Rallybio shifts gears, cashing out of Recursion pact
Rallybio has swerved away from its Recursion pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway.
Nick Paul Taylor
Jul 8, 2025 8:59am
RallyBio cuts deeper, laying off 40% of workforce
May 8, 2025 9:00am
Rallybio drops lead program as phase 2 data disappoint
Apr 8, 2025 8:52am
Rallybio reins in preclinical, Monopar pivots to radiopharma
May 9, 2024 10:13am
J&J funds Rallybio in risk-busting rare pregnancy disease pact
Apr 10, 2024 4:00pm
Rallybio drops 45% of workforce to extend cash runway into 2026
Feb 6, 2024 9:45am
